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Objectives. To find potential diagnostic markers or therapeutic targets, we used differential display technique to
identify genes that are over or under expressed in human ovarian cancer.
Methods. Genes were initially identified by differential display between two human ovarian surface epithelium
cultures and two ovarian cancer cell lines, A2780 and Caov-3. Genes were validated by relative quantitative
RT-PCR and RNA in situ hybridization.
Results. Twenty-eight non-redundant sequences were expressed differentially in the normal ovarian epithelium
and ovarian cancer cell lines. Seven of the 28 sequences showed differential expression between normal ovary
and ovarian cancer tissue by RT-PCR. USP36 was over-expressed in ovarian cancer cell lines and tissues by
RT-PCR and RNA in situ hybridization. Northern blot analysis and RT-PCR revealed two transcripts for USP36 in
ovarian tissue. The major transcript was more specific for ovarian cancer and was detected by RT-PCR in 9/9
ovarian cancer tissues, 3/3 cancerous ascites, 5/14 (36%) sera from patients with ovarian cancer, and 0/7 sera
from women without ovarian cancer.
Conclusion. USP36 is overexpressed in ovarian cancer compared to normal ovary and its transcripts were
identified in ascites and serum of ovarian cancer patients.
Key words: ovarian cancer; biological markers; ubiquitin specific peptidase 36 (USP36); deubiquitinating enzyme

Introduction
Ovarian cancer, the most fatal gynecological
cancer, is ranked fourth in overall cancer mortality
among women in the United States, causing ~16,000
deaths per year [1]. A woman’s estimated risk of
developing ovarian cancer in her lifetime is 1 in 70 or
1.4%. Unfortunately, no fully effective mass screening
method for early ovarian cancer has yet been
developed. The currently available methods, such as
abdominal and transvaginal ultrasonography, color
flow Doppler, and CA-125, are not specific enough for
detecting early, treatable ovarian cancer through
population screening [2]. Therefore, the disease is
detected at an advanced stage in most patients, being
confined to the ovaries at diagnosis in fewer than 30%
of cases.
Epithelial ovarian cancer develops from a clone of
cells [3], which suggests that early stages of the disease
could be detected if specific tumor markers expressed

at early stages could be identified. To find potential
diagnostic markers for early ovarian cancer, we used
differential display previously described [4] for
identifying key genes that were uniquely
overexpressed or silenced in ovarian cancer compared
with normal cells. As more than 85% of human ovarian
cancers are thought to be derived from ovarian surface
epithelium (OSE) [5], we performed differential
display to compare gene expression patterns in two
cultured OSE cells and two human ovarian cancer cell
lines, A2780 and Caov-3. We used relative quantitative
RT-PCR and RNA in situ hybridization techniques to
further evaluate the differentially expressed genes.
USP36 was confirmed over-expressed in ovarian
cancer cell lines and tissues. The USP36 predominant
transcript was further characterized in multiple
human tissues, cancerous ascites, and sera from
women with and without ovarian cancer.
In
eukaryotic
cells,
ubiquitination
and
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deubiquitination regulate a number of biological
processes by balancing cellular protein degradation.
This post-translational modification is a dynamic and
reversible process controlled by the coordinate action
of
multiple
ubiquitin-conjugating
and
deubiquitylating enzymes. USP36 is one of the
deubiquitinating (DUB) enzymes and belongs to
ubiquitin-specific processing proteases (USP). USP
removes ubiquitin from specific protein substrates and
allow protein salvage from proteasome degradation,
regulation of protein localization or activation [6].
Previous studies demonstrated that USP36 has DUB
activity both in vivo and in vitro [7, 8].

T75 polystyrene flask and added 10 ml of prewarmed
(37°C) medium. The medium was changed on the next
day to remove debris and then changed every 3-4 days.
When the cells in the flask were confluent, they were
trypsinized and RNA was extracted.
The A2780 cell line was cultured in RPMI 1640
medium. The Caov-3 cell line was cultured in
Dulbecco's modified Eagle's medium (DMEM). Both
media were supplemented with 10% FBS, 2 mM
L-glutamine, 103 IU/ml of penicillin and 103 μg/ml of
streptomycin. The cell lines were cultured in 5% CO2 at
37°C.

Materials and methods

Total cellular RNA was isolated from the cell
lines by the guanidinium isothiocyanate method [10].
Contaminating DNA was removed with the
MessageCleanTM Kit (GenHunter Co., Nashville, TN).
Differential display technique was first described by
Liang and Pardee in 1992[4]. Since then the technique
has been applied in numerous studies. We
performanced the differential display using the
RNAimageTM kit (GenHunter Co. Nashville, TN),
following the manufacturer’s instructions.
Total RNA was reverse transcribed using the
primer
H-T11A
(5'-AAGCTTTTTTTTTTTA-3'),
H-T11G (5'-AAGCTTTTTTTTTTTG-3'), or H-T11C
(5'-AAGCTTTTTTTTTTTC-3'). The product was
amplified by PCR using one of the primer pairs labeled
with alpha-[35S]-dATP. Overall, 24 primer pairs were
used for PCR, including combinations of each of the
above three primers with
H-AP49 (5'-AAGCTTTAGTCCA-3'),
H-AP50 (5'-AAGCTTTGAGACT-3'),
H-AP51 (5'-AAGCTTCGAAATG-3'),
H-AP52 (5'-AAGCTTGACCTTT-3'),
H-AP53 (5'-AAGCTTCCTCTAT-3'),
H-AP54 (5'-AAGCTTTTGAGGT-3'),
H-AP55 (5'-AAGCTTACGTTAG-3'), or
H-AP56 (5'-AAGCTTATGAAGG-3').
All PCR products were electrophoresed in parallel on
extended-format denaturing 6% polyacrylamide gel
and displayed by autoradiography.

Cell cultures and tissue samples
Tissue samples from normal ovaries and ovarian
cancers were obtained from women undergoing
oophorectomies. RNA from other human tissues was
obtained from the Tissue Procurement Core at the
Siteman Cancer Center. The study was approved by
the Human Studies Committee of Washington
University in St. Louis.
Human OSE cells were collected according to the
method described by Kruk et al [9] and cultures were
maintained in a mixture of Medium 199 with Earle’s
balanced salt solution (Sigma, St. Louis, MO) and
MCDB105 (Sigma, St. Louis, MO) (1:1, pH 7.3)
supplemented with 15% FBS (medium 199/105/15%
FBS) and 2 mM L-glutamine. The medium contained
103 IU/ml of penicillin and 103 μg/ml of streptomycin
and fungizone (250 ng/ml) for the first week. Cells
were plated onto a T25 polystyrene flask with 5 ml of
medium and incubated undisturbed at 37°C in 5%
CO2/air for 48 hours. The old medium, which
contained blood and debris, was replaced with fresh
prewarmed (37°C) medium. Subsequently, the culture
medium was changed every 3-4 days as needed. When
the culture was confluent, the cells were subcultured
with trypsin/EDTA (Life Technologies, Gaithersburg,
MD).
To characterize the cultured cells, we added 3-4
drops (50-100 μl) of prewarmed medium into each well
of a microscope slide well chamber (16 wells/slide).
Two drops of trypsin/EDTA/cell mixture were seeded
into each well. The medium was changed every 3-4
days until the cells were confluent. Then cells were
fixed in methanol/acetone and stained for cytokeratin
and vimentin using anti-cytokeratin AE1/AE3
(Boehringer Mannheim, Indianapolis, IN) and
anti-vimentin (Boehringer Mannheim, Indianapolis,
IN) following the manufacturer’s instructions.
To propagate the cells and extract their RNA, we
placed the remaining trypsin/EDTA/cell mixture in a

Differential display

cDNA cloning and sequencing
PCR products of the RNAs that were found to be
differentially expressed between OSE cell lines and
ovarian cancer cell lines were cut out from a
polyacrylamide gel, re-amplified with the same primer
pair, purified on agarose gels using the QIAquick Gel
Extraction Kit (QIAGEN, Valencia, CA), and then
cloned into the pCR-TRAP Cloning SystemTM
(GenHunter Co., Nashville, TN). The inserts of clones
were sequenced using either the Lgh and or Rgh
primer flanking the cloning site. All sequencing
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reactions were performed ustilizing ABI PRISMTM
BigDyeTM Terminator Cycle Sequencing Ready
Reaction Kit (Perkin Elmer, Foster City, CA).

RT-PCR
Relative quantitative RT-PCR was performed
according to the method of Nicoletti and Sassy-Prigent
[11], with some modification. RNA samples were
diluted to 1 μg/4 μl (assessed by OD260). One μg of
each mixed RNA (normal and cancer) sample was
used for reverse transcription in a reaction mixture
whose final volume was 20 μl. The mixture contained 1
μg of oligo(dT)15, 200 U of MMLV reverse
transcriptase, 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3
mM MgCl2, 10 mM dithiothreitol (DTT), 20 U RNase
inhibitor (Promega, Madison, WI), and 0.5 mM each of
dNTP and 0.1% DEPC (Sigma, St. Louis, MO). It was
incubated at 37°C for 60 min.
The primers were designed using the Primer 3
program (http://www.genome.wi.mit.edu/cgi-bin/
primer/primer3_www.cgi). Multiplex PCR was
performed in a total volume of 20 μl that contained 0.5
μM of each primer, 500 μM each of dNTP, 10 mM
Tris-HCl (pH 8.3), 50 mM KCl, 6 mM MgCl2 and 2.5 U
of AmpliTaq DNA Polymerase (Perkin-Elmer,
Norwalk, CT). An endogenous housekeeper gene,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as an internal standard to correct for tube-to-tube
variations in amplification efficiency. The PCR
thermocycles were: 4 min at 94°C, (1.5 min at 94°C, 2
min at 55°C, and 3 min at 72°C)20, and 10 min at 72°C.
A minus RT-PCR reaction was included for every RNA
sample to confirm the absence of contaminating DNA.
Quantitative data on the PCR products were
acquired by digitizing photographs of ethidium
bromide-stained agarose gel into gray-scale images
using the public NIH Image 1.71 program and by the
Wave
DNA
Fragment
Analysis
System
(Transgenomic, Omaha, NE).

RNA in situ hybridization
RNA in situ hybridization was performed using a
digoxigenin (DIG) labeled riboprobe. Sense and
antisense riboprobes were synthesized separately and
labeled in total volume of 20 µl. The reaction mixture
contained 1 x transcription buffer, 1 x DIG RNA
labeling mixture from the DIG Genius 4 RNA Labeling
Kit (Boehringer Mannheim, Indianapolis, IN), 5 mM
DTT, 20 U of RNase inhibitor (Promega, Madison, WI),
40 U of T7 or SP6 RNA polymerase (Promega,
Madison, WI), and 60 ng of linearized DNA templates.
The templates were generated from the PCR products
amplified using T7 and SP6 primer (GenHunter Co.,
Nashville, TN) from IMAGE clone 2400019. The
generated antisense probe for USP36 is 267bp (5’-
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ggatccatttaggtgacactatagaagtacctgaaaggaagcttttttttttcg
aggatttcctgtatttattaagttacaagttggcaggcacagcttgagcaacat
agaaaagtaatcttcttgagttatacaatcatttaaattccaaagcactcacaa
aattgagcaaacaaagccactatttgcatatttgggaaaggaaacatattgct
aacgtaagcttcctgaatccttcatggcctatagtgagtcgtattagaattc-3’
). The synthesized riboprobe was precipitated by
ethanol and verified by RNA electrophoresis.
Formalin-fixed paraffin-embedded tissue slides were
deparaffinized in Hemo-De (Fisher Scientific,
Pittsburgh, PA), rehydrated in serially diluted ethanol
(100%, 95%, 70%, 50%, and 30%), digested in 2 µg/ml
proteinase K at 37ºC for 30 min, and then rinsed 3
times in PBT (PBS containing 0.1% Tween 20 and 0.1%
DEPC). The pretreated slides were hybridized at 55ºC
overnight in a buffer containing 50% formamide, 5 x
SSC, 100 µg/ml Salmon Sperm DNA, 100 µg/ml
heparin, 0.1% Tween 20, 1 x Denhardt’s medium, 0.1%
CHAPS, 5 mM EDTA, and ~16 µg/ml DIG-labeled
riboprobe. After the slides were rinsed with 0.1 x SSC
and blocked with blocking buffer (5% sheep serum, 2
mg/ml BSA, and 1% DMSO in PBT), DIG-labeled
riboprobe was detected with anti-digoxigenin-AP, Fab
fragments (Boehringer Mannheim, Indianapolis, IN),
according to manufacture’s instructions.

Northern blot
mRNA was extracted by the Messenger RNA
standard isolation kit (Sigma, St. Louis, MO), and total
RNA was extracted by the ToTALLY RNA kit
(Ambion, Austin, TX). The products were
electrophoresed on 1.5% formaldehyde/1% agarose
gel with RNA MilenniumTM Size Marker (Ambion,
Austin, TX). The RNA was transferred from the gel to
BrightStar-PlusTM Membranes (Ambion, Austin, TX)
and cross-linked onto the membrane with UV.
Single-strand DNA probes labeled with 32P dCTP were
made by asymmetric PCR, using antisense primer and
same template as in RNA in situ hybridization. The
synthesized probe was purified on a centrifuge
column, and its specific activity was measured by
liquid scintillation analysis. The probe for USP36 is
130bp (5’- ttacaagttggcaggcacagcttgagcaacatagaaaagt
aatcttcttgagttatacaatcatttaaattccaaagcactcacaaaattgagca
aacaaagccactatttgcatatttgggaaaggaaa-3’).
The
membrane was hybridized in buffer containing 1.6 x
107 cpm/ml probe and 6.0 x 104 cpm RNA
MilenniumTM Size Marker (Ambion, Austin TX) at
50ºC for 16 h. The membrane was rinsed with low
stringency solution 2 x SSC and 0.1% SDS at 50ºC for 15
min and then autoradiographed at -70°C with
intensifier screen.

Isolation of RNA from ascites and serum
Serum was isolated and stored at -70°C until
processed. Ascites was collected at surgery and
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centrifuged at 4°C for 5 minutes at 150g. The
supernatant was removed and stored at -70°C until
processed. Isolation of RNA was preformed using
TRIzol® LS Reagent (Invitrogen Corporation,
Carlsbad, CA) or magnetic bead method - Ambion’s
MagMaxTM technology (Ambion, Inc., Austin, TX)
following manufactures’ protocol. DNA and RNA
input levels ranging from 20 copies to 25x106 copies
can be quantitatively recovered from plasma, serum,
and milk (MagMaxTM manual). The concentration and
purity of RNA were determined by using the
Nanodrop® ND-1000A UV-Vis Spectrophotometer
(NanoDrop Technologies, Wilmington, DE) and
Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.
Santa Clara, CA). The concentration of RNA extracted
from the sera range from 0.2 ~ 26ng/ul, which is
similar with the results from a recent study [12]. RNA
was
processed
for
cDNA
using
Ambion
RETROscript® Kit (Ambion, Inc.Austin,TX). An
internal standard, RPS14, was used to confirm the
RNA quality suitable for RT-PCR.

Results
Human OSE cell lines
Cultures of OSE cells were characterized by
immunostaining
with
monoclonal
antibodies,
anti-keratin AE1/AE3 and anti-vimentin. The
anti-keratin
AE1/AE3
monoclonal
antibody
specifically recognizes human epithelial cytokeratin,
an intermediate filament in epithelial cells that is
absent from mesenchymal cells such as fibroblasts and
smooth muscle cells. The anti-vimentin monoclonal
antibody was used to stain cells of mesenchymal
origin, including endothelial cells, vascular smooth
muscle cells, connective tissue cells, and all types of
blood cells. Immunostaining with both antibodies
confirmed the epithelial origin of 6 human OSE cell
cultures and 2 cell lines (N 1/4 and N 1/29) were used
for the differential display.

Genes expressed differentially between human OSE
cells and ovarian cancer cell lines
Thirty-one bands were differentially expressed
between the 2 human OSE cell lines and 2 ovarian
cancer cell lines (A2780 and Caov-3). Among those 31
bands, 15 were significantly overexpressed in the two
ovarian cancer cell lines compared with the two
normal OSE cell lines and 16 were expressed at lower
levels in the two ovarian cancer cell lines than in the
two OSE cell lines. Figure 1 provides an example of
differential expression.
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Figure 1 Differential display of human OSE cells and
ovarian cancer cell lines. Each vertical panel represents one
primer pair, and every primer pair includes 4 different cell lines:
N1 (N1/4), N2 (N1/29), C1 (A2780), and C2 (Coav-3). The left
panel shows bands that are expressed at a higher level in the
normal human OSE cell lines N1/4 and N1/29 (bands A, B, C,
and D) than in the cancer cell lines. The right panel shows the
bands that are overexpressed in the human ovarian cancer cell
lines A2780 and Coav-3 (bands E, F, and G). G1 and G2 are
different bands with identical sequences.

We cloned all 31 differentially expressed bands
into pCR-TRAP vectors. The clones were screened
according to the size of the inserts, using PCR and the
primer pair that flanked the cloning site of the
pCR-TRAP vector and then sequenced. For two bands,
two different sequences with similar sizes were
identified. Therefore, a total of 33 different cloned
sequences were obtained.
To identify these sequences, we used the blastn
algorithm to query three nucleotide sequence
databases
on
the
NCBI
website
(http://www.ncbi.nlm.nih.gov): nr (non-redundant),
dbEST, and dbSTS. The 33 clones represented 28
nonredundant
sequences.
Fourteen
were
underexpressed in both cancer cells lines and 14 were
overexpressed in both cancer cell lines. Among the 28
nonredundant sequences, 22 matched known genes or
EST, rest of them either matched to genomic DNA that
contained no known EST or intron of known gene
(Table 1).

Validation of differential expression in human ovarian
tissues
To confirm that the 28 non-redundant sequences
were expressed differentially in the normal human
ovary and ovarian cancer tissues, we performed
relative quantitative RT-PCR, using four normal
human ovary tissue samples (NO1, NO2, NO3, and
NO4) and four human ovarian cancer tissue samples
(OC1, OC2, OC3 and OC4). To obtain a relative
quantitative measurement of the gene expression, an
alternative quantitative PCR method was used [11].
First, a series of 5 progressive dilutions achieved by
mixing RNAs of tumor (T) and matched normal (N)
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samples (T4/N0, T3/N1, T2/N2, T1/N3 and T0/N4)
were assembly. Then an aliquot of each dilution mix
was submitted to a standard RT-PCR. After PCR, the
photographs of ethidium of bromide-stained gels were
digitized into gray-scale images. The amount of
nucleic acids was determined by densitometry. The
amount of nucleic acid was proportional to the log of
the optic density. The sum of the logarithms of the
pixel values was used to estimate the amount of
nucleic acid in a band. The fold increase was compared

based on the expression of normal sample (T0/N4).
The internal control of GAPDH was used to correct for
tube-to-tube variations in initial sample inputting. In
addition, we did the semi-quantitative RT-PCR using
minimal cycling to avoid the artificial effect of
saturation of PCR products. Seven of the 28 sequences
showed differential expression between the normal
and cancer tissues by relative quantitative RT-PCR
(Table 2 and 3).

Table 1. Genes (EST) identified in this study.
Clone
a & b-1
b-2
2
3
11
12
13
14
15
16
17 & 20 & 34
17 & 20 & 34
18
21
23
4
10
19
22
24
25
26-1
26-2
27 & 28
29 & 32
30
31
35
36-1

Band *

A

B
C
D

E

F
G

Tissue over expressed
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer

UniGene ID
N/A
Hs.471234
Hs.592304
Hs.348319
Hs. 40098
Hs.369920
N/A**
Hs.655420
Hs.459790
Hs.210469
Hs.380953
Hs.713533
Hs.370140
Hs.75813
Hs.190028
N/A
N/A
Hs.75277
Hs.75527
Hs.107474
Hs.486095
N/A
Hs.464243
Hs.460298
Hs.22857
N/A
N/A
Hs.184233
Hs.656195

Gene
OK/SW-cl.16
CCNYL1
ERO1L
Transcribed locus
GREM1
RAP1B
Genomic sequence
AMDHD2
VPS13A
ELMO2
RPL38
LTBP1
HELZ
PKD1
GSTO1
Genomic sequence
Genomic sequence
RMND5A
ADSL
Transcribed locus
PDSS2
Genomic sequence
USP36
POLR3E
CHORDC1
Genomic sequence
Genomic sequence
HSPA9
C21orf51

Chromosome Location
1p36.33
2q33.3
14q22.1
Chr. 10
15q13-q15
12q14
16p13.3
9q21
20q13
17q23-q25
2p22-p21
17q24.2
16p13.3
10q25.1

2p11.2
22q13.2
Chr. 2
6q21
17q25.3
16p12.1
11q14.3

5q31.1
21q22.12

*Band: differentially expressed genes, which validated by RT-PCR (Table 2 and Table3), in normal or tumor ovary cell lines.
**N/A: not available

Table 2.

Genes identified by differential display (increased in normal ovary or ovarian cancer) and validated by RT-PCR.
GeneID

Gene name

15q13-q15

Gene
Symbol
GREM1

26585

Normal

2p22-p21

LTBP1

4052

C

Normal

16p13.3

PKD1

5310

D
E

Normal
Cancer

10q25.1
2p11.2

GSTO1
RMND5A

9446
64795

F
G

Cancer
Cancer

17q25.3
16p12.1

USP36
POLR3E

57602
55718

gremlin 1, cysteine knot superfamily, homolog
(Xenopus laevis)
latent transforming growth factor beta binding
protein 1
polycystic kidney disease 1 (autosomal
dominant)
glutathione S-transferase omega 1
required for meiotic nuclear division 5 homolog
A (S. cerevisiae)
ubiquitin specific peptidase 36
polymerase (RNA) III (DNA directed)
polypeptide E (80kD)

Band

Tissue over expressed

Chromosome Location

A

Normal

B
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Table 3. Relative expression levels of the seven genes in four normal human ovary tissues and four human ovarian cancer tissues.
Band

Gene

NO1

NO2

NO3

NO4

OC1

OC2

OC3

OC4

A
B
C
D
E
F
G

GREM1
LTBP 1
PKD1
GSTO1
RMND5A
USP36
POLR3E

ND
+
+
-

+
++
+
-

++++
+
ND

+
++
++
+
-

ND
+
++++
-

+
+++

+
++++
ND

+
++
+++

ND: No data;
-: no increase or increase < 2 times;
+: Increased 2~10 times; ++: Increased 10~100 times; +++: Increased 100~1000 times; ++++: Increased more than 1000 times;
NO = normal ovary, OC = ovarian cancer

The three over-expressed sequences in ovarian
cancer tissue confirmed by RT-PCR were USP36,
RMND5A, and POLR3E. We further evaluated the
expression of these 3 genes by RNA in situ
hybridization, using nine ovarian cancer tissues
(including endometroid adenocarcinoma, serous
adenocarcinoma, borderline serous tumor, papillary
serous adenocarcinoma, clear cell adenocarcinoma,
and mixed epithelial type adenocarcinoma) and eight
matched normal ovaries or fallopian tubes from the
same patients. A sense probe was used as the negative
control. For USP36, all nine ovarian cancer tissues gave
a strong positive signal (Figure 2, panels A-D) and
eight normal tissues gave very weak or negative
results in the surface epithelium, stroma, and follicles
(Figure 2, panels E and F). For RMND5A, six of the
nine ovarian cancer tissues were positive and all the
normal tissues were weak or negative. For POLR3E,
four of the nine ovarian cancer tissues gave positive
results and all the normal tissues showed weak or
negative staining.
Figure 2 RNA in situ hybridization of USP36. A and B show
a well-differentiated endometrioid adenocarcinoma hybridized
with antisense (A) and sense (B) riboprobe. C and D show a
poorly differentiated carcinoma of mixed epithelial origin,
endometrioid, and papillary serous hybridized with antisense
(C) and sense (D) riboprobe. E and F are from normal ovary
hybridized with antisense (E) and sense (F) riboprobe.

The predominant transcripts of USP36 and RMND5A
in ovarian cancer cell lines
Northern blot analysis revealed two transcripts
for USP36, ~6.0 kb (major transcript) and ~4.7 kb
(minor transcript) (Figure 3). USP36 locates on
chromosome 17q25.3 and covers 44571 bp genomic
sequences. Seventeen mRNAs and 482 EST sequences
represent human USP36 in NCBI UniGene database
(http://www.ncbi.nlm.nih.gov/UniGene). The ESTs
come from almost every tissue, including ovary and
cervix.
The
sequence
alignment
between

representative mRNA and the genomic sequence
indicates that these mRNAs are spliced transcript
variants of the USP36 gene (Figure 4). Among these
mRNAs, AB040886 (NM_025090, 5879 bp) and
AK022840 (4650 bp) most closely match the major and
minor transcripts seen in the Northern blot (Figure 3).
The sequence from the differential display band F
(Table 2 and 3) perfectly matches both mRNAs, but
only the AK022840 transcript contained the
homologous 3’ end identified by initial differential
display (Figure 4).
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Figure 3 Northern blot. Lanes A and C are RNA Size
Marker; lanes B and D are mRNAs (10 µg polyA RNA in each
lane) from the A2780 cell line. The first panel is USP36 and the
second panel is RMND5A.

To confirm which transcripts are expressed in
ovarian cancer, we designed 6 RT-PCR primers that
detect specific mRNAs (Table 4, Figure 4). All primer
pairs except USP36-2 were designed to cross an intron
to eliminate interference by any contaminating
genomic DNA. RT-PCR results demonstrated the
expression of AB040886 (~ 6 kb) and AK022840 (~4 kb)

in ovarian cancer cell lines (Figure 5) and were
consistent with the Northern blot results. AB040886
has 21 exons, encodes a protein with 1121 amino acid
(aa) and contains one ubiquitin carboxyl-terminal
hydrolase (UCH) family 2 motif. AK022840 has 16
exons and encodes a protein with 726 aa and contains
part of the ubiquitin carboxyl-terminal hydrolase
(UCH) domain.
Northern blot analysis revealed two transcripts
for RMND5A (~6.0 kb and ~2.5 kb) by using mRNA
from ovarian cancer cell line A2780 (Figure 3). The
sequence RMND5A resides on chromosome 2p11.2
and covers 57756 bp genomic sequences. Several
mRNAs corresponding to this gene are documented
on the NCBI website. Recent study showed that
RMND5A (p44CTLH) was associated with several
proteins and composed a large protein complexes. It
contains LisH/CTLH motifs, which are present in
proteins involved in microtubule dynamics, cell
migration,
nucleokinesis,
and
chromosome
segregation [13].

Table 4. RT-PCR primer set and target mRNA.
Primer
Name

Forward Primer
(5’ – 3’)

Reverse Primer
(5’ – 3’)

Target
mRNA

mRNA
(bp)

PCR
(bp)

USP36-1
USP36-2
USP36-3
USP36-3A
USP36-4
USP36-5

GTCATCTTGCTGAGCCCTTC
AATTTTGTGCTTGGGAATGG
ATGTGGTCCAGGAACTGCTC
ATGACTGGGACGAAGAGTTTGAC
GAAAGGAGGTGCAGAGGATG
ACTCTCCCAGACACCCACAC

GGCATTCTCTCCACTCAGGA
TTTTTTTCACAGAACCGGAG
CCCACCTCACCCTTACACC
CTACACACATACACGGCACACAC
CTGTGCCTGCCAACTTGTAA
TGGAACAGTTCGTTTCCTGA

AK022840
AK023077
AB040886
AB040886
AI963973
AK022913*

4650
2479
5879
5879
423
3760

255
223
359
247
211
247*

* USP36-5 primer set also detects AK022840 and AB040886 as a 389 bp PCR product.

Figure 4 Transcripts for USP36 and primer location. A. Schematic representation of five USP36 transcripts from cDNA clones.
Tel: telomere end; Cen: centromere end. B. The positions of five primers and band F are indicated schematically. Each RT-PCR
primer is designed to cross introns (except primer USP36-2) and to detect a specific mRNA transcript.
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Figure 5 Determination of USP36 transcripts by RT-PCR.
Column 1-5 represent primers USP36-1 to USP36-5, and
column M represents a 100 bp DNA ladder. Primers USP36-1
(AK022840) and USP36-3 (AB040886, NM_025090) were
positive. Primer pairs USP36-4 (AI963973) and USP36-2
(AK023077) represent genomic DNA. Primer USP36-5
(AK022913) detected a 389 bp band which matches AB040886
and AK022840 but was negative for the 247 bp band specific for
AK022913 (Figure 4).

Expression pattern of USP36 mRNA transcripts in
multiple human tissues
We further evaluated the expression of USP36
major transcript AB040886 and minor transcript
AK022840 in multiple human tissues by RT-PCR.
USP36-3A was developed to identify AB040886 with a
smaller PCR product in serum and ascites (Table 4).
The results showed that the major transcript AB040886
is more specific for ovarian cancer tissue than the
minor transcript AK022840. AB040886 was detected in
9/9 human ovarian cancer tissues, 3/3 ascites
specimens from ovarian cancer patients, and 5/14
(36%) sera from ovarian cancer patients. Sequencing
two of five PCR products from sera confirmed the
result. None of seven sera from women without
ovarian cancer detected AB040886.
As comparison to ovarian cancer, 4 normal
ovaries tissues showed absent expression except one
hemorrhagic torsed benign ovary had expression
similar to ovarian cancer. In addition, AB040886
showed absent expression in normal tissues from
pancreas, kidney, cervix, spleen, testis, endometrium,
breast, colon, myometrium, and liver by RT-PCR.
There was minimal to absent staining in cancers from
prostate, cervix, colon, lung and breast. AK022840 was
ubiquitously expressed in all tested tissues.

Discussion
To identify overexpressed or silenced genes in
ovarian cancer, we used differential display to
compare human ovarian cancer cell lines with human
normal OSE cell lines. We detected 28 differentially
expressed genes. When we used RT-PCR and RNA in
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situ hybridization to validate the differential
expression of these sequences in human normal
ovarian tissue and ovarian cancers and found that
USP36 was consistently overexpressed in the ovarian
cancers tissues evaluated. RNA in situ hybridization
showed USP36 expression in various histologic types
of epithelial ovarian cancer. Northern blot and RT-PCR
identified two transcripts. The major transcript
AB040886 appears more specific for ovarian cancer
tissue than the minor transcript AK022840.
USP36 is a deubiquitinating enzyme, also known
as
ubiquitin
specific
protease
(USP).
The
deubiquitinating enzymes are a component of the
ubiquitin system, which is important for regulating
numerous basic biological processes, including
cell-cycle progression, apoptosis, signal transduction,
transcriptional regulation, receptor downregulation,
and endocytosis [14]. Like protein phosphorylation
and dephosphorylation, protein ubiquitination is a
dynamic process. It is controlled by the coordinated
actions of ubiquitin conjugating enzymes and
deubiquitinating enzymes that respectively add or
remove the ubiquitin moiety from a target protein. The
deubiquitinating enzymes are also involved in
processing of poly-ubiquitin precursors into ubiquitin
monomers, targeting or salvage of proteasomal
substrates and regulating nonproteolytic functions of
mono- and poly-ubiquitination [15, 16].
Ubiquitin-mediated
proteolysis
has
been
implicated in the degradation of several important
oncogene products, such as N-myc, c-myc, c-fos, c-jun,
β-catenin, and adenovirus E1A [14]. Aberrations in
their removal may derail the cell cycle and result in
malignant
transformation.
UCH-L1,
a
deubiquitinating enzyme, is highly expressed in
primary lung cancers and lung cancer cell lines and
strongly correlates with advanced stage [17, 18]. Yeast
two-hybrid analysis showed UCH-L1 interacts with
JAB1, a Jun activation domain binding protein that can
bind to p27Kip1 [19]. Another deubiquitinating enzyme,
Unp (USP4) is tumorigenic when overexpressed in
mice, acting like a proto-oncogene [20].
USP36 cloning and enzymatic analysis was
published by Quesada et al. along with 21 other novel
human ubiquitin-specific proteases. Northern blot
analysis showed USP36 to be present in leukocytes,
ovary, testis, and prostate at about ~ 7.5 kb (probe
information not provided, there is no size marker to
indicate the band size) [8]. According to the provided
protein IDs in the paper, NP_079366 matches USP36.
The protein is 1123aa and the encoding mRNA is
NM_025090 (5234bp) (http://www.ncbi.nlm.nih.gov).
It is exactly the same protein we described in this
study (AB040886, encoding USP36, 1123aa). Enzymatic
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assays demonstrated that USP36 had USP activity.
Kim et al. identified USP36, called HeLa DUB-1, in
extracts from HeLa by RT-PCR with a pair of primers
designed for AK022913 [7, 21]. Although these
publications stated USP36 was isolated from ovarian
cancer, HeLa is a cervical cancer cell line [22].
According to the published sequence, the HeLa DUB-1
cDNA is a different transcript from the major
transcript (AB040886) of ovarian cancer cell lines
described in this paper and corresponds to AK022913
(but with different 3’ and 5’ terminals). Our RT-PCR
results indicated that AK022913 is not expressed in
human ovarian cancer cell lines (Figure 5, lane 5). In
Kim’s paper, they mentioned that USP36 contains 18
exons.
According
to
the
same
website
http://genome.ucsc.edu/ (version March 2006),
USP36 contain 21 exons, in which 18 of them are
coding exons.
Circulating nucleic acids (CNA) was first
reported in 1940s. In 1977, Leon et al. first reported
high levels of CNA in patients with pancreatic cancer.
In 2007 the use of CNA was proposed as a
non-invasive tool for the early detection of cancer [23].
Recent studies have shown circulating RNA may be
used as a valuable diagnostic tool for discriminating
cancer patients from non-cancer individuals. Li et al.
demonstrated that the mRNA profile was more
complex in sera from oral squamous cell carcinoma
patients than that in healthy controls using microarray
and RT-PCR techniques [24]. Feng et al. found that the
mean level of RNA in serum of patients with renal cell
cancer was significantly higher than that in healthy
individuals.[12] Here we demonstrated that USP36
mRNA could be detected in 5/14 (36%) sera by
RT-PCR from ovarian cancer patients. Additional
studies are needed to validate these findings.
In summary, using differential display, RT-PCR,
and RNA in situ hybridization we confirmed the
overexpression of USP36 in human ovarian cancer
compared to normal ovaries. USP36 was detectable by
RT-PCR in ovarian cancer tissue, ascites and serum
specimens from ovarian cancer patients. Further work
is necessary to identify the specific target of USP36 and
to determine the role of this deubiquitinating enzyme
in ovarian carcinogenesis or its prospect as a cancer
biomarker.
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